WHO ICTRP trial
Clinical efficacy of Qianmitong in the treatment of Chronic prostatitis with…
ChiCTR2100046366 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2100046366 |
|---|---|
| Public title | Clinical efficacy of Qianmitong in the treatment of Chronic prostatitis with qi-stagnancy and blood stasis Syndrome |
| Scientific title | Clinical efficacy of Qianmitong in the treatment of Chronic prostatitis with qi-stagnancy and blood stasis Syndrome |
| Primary sponsor | Hospital of Chengdu University of Traditional Chinese Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | Chronic prostatitis |
| Interventions | Treatment group:Qianmitong tablet + tamsulosin hydrochloride sustained release capsule placebo;Control group:Tamsulosin hydrochloride sustained release capsule + Qianmitong tablet placebo |
| Registration date | May 14, 2021 |
| Target size | Treatment group:73;Control group:73 |
| Secondary IDs | ChiMCTR2100004846 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: